Evidence map›Paper›PMID 34993350›Full record

ArticleBMJ open ophthalmology2021

Impact of benzalkonium chloride-preserved and preservative-free latanoprost eye drops on cultured human conjunctival goblet cells upon acute exposure and differences in physicochemical properties of the eye drops.

Olivia Müllertz, Anne Hedengran, Zaynab Ahmad Mouhammad, Josefine Freiberg, Richárd Nagymihály, Jette Jacobsen, Susan Weng Larsen, Jeffrey Bair, Tor P Utheim, Darlene A Dartt and 3 more

Open access · goldAbstract read
In one paragraph

Article in BMJ open ophthalmology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 17 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 3 countries.

Olivia Müllertz *Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark.
Anne Hedengran *Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark.ORCID 0000-0002-7556-4658
Zaynab Ahmad MouhammadDepartment of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark.
Josefine FreibergDepartment of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark.ORCID 0000-0003-1520-7226
Richárd NagymihályCenter for Eye Research, Department of Ophthalmology, Oslo University Hospital and Institute for Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.
Jette JacobsenDepartment of Pharmacy, University of Copenhagen, Copenhagen, Denmark.
Susan Weng LarsenDepartment of Pharmacy, University of Copenhagen, Copenhagen, Denmark.
Jeffrey BairMassachusetts Eye and Ear Infirmary, Department of Ophthalmology, Harvard Medical School, Schepens Eye Research Institute, Boston, Massachusetts, USA.
Tor P UtheimDepartment of Medical Biochemistry, Oslo Universitetssykehus, Oslo, Norway.
Darlene A DarttMassachusetts Eye and Ear Infirmary, Department of Ophthalmology, Harvard Medical School, Schepens Eye Research Institute, Boston, Massachusetts, USA.ORCID 0000-0002-0576-6932
Steffen HeegaardDepartment of Ophthalmology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
Goran PetrovskiCenter for Eye Research, Department of Ophthalmology, Oslo University Hospital and Institute for Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.
Miriam KolkoDepartment of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark.ORCID 0000-0001-8697-0734
University of Copenhagen · DKMassachusetts Eye and Ear Infirmary · USOslo University Hospital · NOCopenhagen University Hospital · DKSørlandet Hospital Arendal · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo investigate the short-term impact on human conjunctival goblet cell (GC) survival and mucin release of acute exposure to benzalkonium chloride (BAK) preserved and preservative-free (PF) 0.005% (w/v) latanoprost (LT) eye drops, and to compare the eye drops' physicochemical properties. METHODS AND ANALYSIS: Primary GC cultures were established from human conjunctival donor tissue. The impact of eye drops on GC survival was assessed using a lactate dehydrogenase assay. Mucin release was evaluated through mucin-specific immunostaining. pH value, osmolality, drop mass and surface tension for all LT eye drops were measured.

resultsAfter application with PF-LT for 30 min (min), the GC survival was maintained compared with control (p=0.9941), while all BAK-LT eye drops reduced survival with approximately 30% (p<0.02). Following application with PF-LT for 30 min, mucin was found around the GC nucleus, as seen in the vehicle control, indicating no secretion. In contrast, BAK-LT caused diffuse staining of mucin, similar to the secretagogue histamine, indicating stimulation of secretion. The pH value of the BAK-LT and PF-LT eye drops were 6.0-6.9 and 6.8, respectively. The osmolality was 258-288 mOsm/kg for the BAK-LT eye drops and 276 for PF-LT eye drops. The mean drop mass was 26-31 mg for the BAK-LT eye drops and 30 mg for PF-LT. The surface tension was lower for all BAK-LT eye drops (31.1-32.1 mN/m) compared with PF-LT (42 mN/m).

conclusionPF-LT compared with various branded and generic LT preparations containing BAK are less cytotoxic when applied to cultured GCs.

Indexed as

drugsexperimental & laboratoryglaucomaocular surface

Identifiers

PMID34993350
PMCPMC8689192
OpenAlexW4200398642

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.